Citation Impact
Citing Papers
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
2012 Standout
Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden
2004
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
2008
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density<SUBTITLE>The Women's Health Initiative Randomized Trial</SUBTITLE>
2003 Standout
Child abuse: Adolescent records vs. adult recall
1990 Standout
Thiazolidinediones
2004 Standout
Mammographic Density and the Risk and Detection of Breast Cancer
2007 Standout
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
2010
Osteoporosis
2019 Standout
Contributions of estrogen to ER-negative breast tumor growth
2006
Design and methods of the Raloxifene Use for The Heart (RUTH) study
2001
Osteoporosis
2006
Chronic inflammation in the etiology of disease across the life span
2019 Standout
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
1999 Standout
Use of doping agents, particularly anabolic steroids, in sports and society
2008 Standout
Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy
2002 Standout
Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
2001 StandoutNobel
Is dehydroepiandrosterone a hormone?
2005
Diagnosis of osteoporosis and assessment of fracture risk
2002 Standout
Primary Care for Survivors of Breast Cancer
2000
Endometriosis
2009 Standout
Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial</SUBTITLE>
2006
Intervention thresholds for osteoporosis in the UK
2004
Combined Screening With Ultrasound and Mammography vs Mammography Alone in Women at Elevated Risk of Breast Cancer
2008 Standout
Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation
2001 Standout
An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex
2014 Standout
Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
2005
Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study
2011
Bone Quality — The Material and Structural Basis of Bone Strength and Fragility
2006 Standout
Intervention thresholds for osteoporosis
2002
Osteoporosis: now and the future
2011 Standout
Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures
2004
Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial
2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
Treatment of postmenopausal osteoporosis
2002
Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial
2001
Epidemiology of breast cancer
2001
Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature
2005
Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture
2006 Standout
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
2004 Standout
Uterine fibroids
2001 Standout
Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms
2014
Geographic trends in incidence of hip fractures: a comprehensive literature review
2011
Endocrine-responsive breast cancer and strategies for combating resistance
2002
Epidemiology of Hip Fractures
1997
Assessing the Risk of Breast Cancer
2000
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
RBPJκ-Dependent Signaling Is Essential for Long-Term Maintenance of Neural Stem Cells in the Adult Hippocampus
2010
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Hip Fracture Incidence among Elderly Asian-American Populations
1997
World-wide Projections for Hip Fracture
1997 Standout
The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
2013
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
2009 Standout
Osteoclast differentiation and activation
2003 StandoutNature
Adult Neurogenesis in the Mammalian Brain: Significant Answers and Significant Questions
2011 Standout
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
PPARγ signaling and metabolism: the good, the bad and the future
2013 Standout
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy
2003
Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures<SUBTITLE>Results From the Fracture Intervention Trial</SUBTITLE>
1998 Standout
Estrogen plus Progestin and the Risk of Coronary Heart Disease
2003 Standout
Similarities and distinctions in the mode of action of different classes of antioestrogens.
2000
Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance
2005
Black-White Differences in Hip Geometry
1998
At what hip fracture risk is it cost-effective to treat?
2006
The Impact of Monitoring on Adherence and Persistence with Antiresorptive Treatment for Postmenopausal Osteoporosis: A Randomized Controlled Trial
2004
Epidemiology of hip fractures: Implications of the exponential increase with age
1996
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases
2008
Evaluation of the risk of hip fracture
1996
Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study
2004
Breast cancer risk assessment models
2002
Gene Expression Profiling of Neural Stem Cells and Their Neuronal Progeny Reveals IGF2 as a Regulator of Adult Hippocampal Neurogenesis
2012
Quantitative Assessment of Mammographic Breast Density: Relationship with Breast Cancer Risk
2004
Epidemiology and outcomes of osteoporotic fractures
2002 Standout
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
2003
Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study
2000
Side Effects of Adjuvant Treatment of Breast Cancer
2001
Preservation of Fertility in Patients with Cancer
2009 Standout
Prevention of falls and consequent injuries in elderly people
2005 Standout
Roles of PPARs in health and disease
2000 StandoutNature
Oestrogen exposure and breast cancer risk
2003
Cancer of the Ovary
2004 Standout
Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club
2005
Bone Density in an Immigrant Population from Southeast Asia
2001
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Prevalence of low femoral bone density in older U.S. women from NHANES III
1995
Noninvasive assessment of bone mineral and structure: State of the art
1996
Bone Resorption by Osteoclasts
2000 StandoutScience
Selective Estrogen Receptor Modulators
2004
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
2008
The Epidemiology of Osteoporosis
1996
A Structural and in Vitro Characterization of Asoprisnil: A Selective Progesterone Receptor Modulator
2007
From Density to Structure: Growing Up and Growing Old on the Surfaces of Bone
1997
Noncardiovascular disease outcomes during 6.8 years of hormone therapy. heart and estrogen/progestin replacement study follow-up (HERS II)
2002
The epidemiology of osteoporosis. The oriental perspective in a world context.
1996
The Epidemiology of Venous Thromboembolism
2003 Standout
Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective Studies
2002 Standout
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
2002 Standout
Who Has Osteoporosis? A Conflict Between Clinical and Public Health Perspectives
2000
A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis.
1999
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance
2008
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling
2005 StandoutScience
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis
2005
Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III
1997
Preclinical Evidence for Therapeutic Efficacy of Selective Estrogen receptor Modulators for Uterine Leiomyoma
2000
Effect of ethnicity and age or menopause on the structure and geometry of iliac bone
1996
Therapeutic Approaches to Bone Diseases
2000 Science
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
2006 StandoutScience
Works of Debra Black being referenced
Racial differences in hip axis lengths might explain racial differences in rates of hip fracture
1994
Latent Stem and Progenitor Cells in the Hippocampus Are Activated by Neural Excitation
2008
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women
1999